Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Region, And Segment Forecasts, 2024 - 2030

Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Region, And Segment Forecasts, 2024 - 2030

Artemisinin Combination Therapy Market Growth & Trends

The global artemisinin combination therapy market size is expected to reach USD 1,018.7 million by 2030, registering a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.

Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.

Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.

WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.

Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.

Artemisinin Combination Therapy Market Report Highlights

• Artemether+Lumefantrine dominated the market and accounted for a share of 37.1% in 2023. The rising demand for Artemether+Lumefantrine can be attributed to its superior effectiveness and safety in treating uncomplicated malaria.
• North America artemisinin combination therapy market held the largest market revenue share of 37.7% in 2023. The increasing demand is primarily due to the rising number of imported malaria cases and the need for effective treatment options.
• Asia Pacific artemisinin combination therapy market is anticipated to grow at the fastest CAGR over the forecast period. The demand for artemisinin combination therapy (ACT) in the.
• Asia-Pacific region is increasing due to the resurgence of malaria and the growing resistance to traditional antimalarial drugs.

Please note The report will be delivered in 2-3 business days upon order notification.